Search results
Results From The WOW.Com Content Network
Cannabis use disorder is recognized in the fifth version of the Diagnostic and Statistical Manual of Mental Disorders , [41] which also added cannabis withdrawal as a new condition. [42] In the 2013 revision for the DSM-5, DSM-IV abuse and dependence were combined into cannabis use disorder.
Substance use disorders can range widely in severity, and there are numerous methods to monitor and qualify the severity of an individual's SUD. The DSM-5 includes specifiers for severity of a SUD. [8] Individuals who meet only two or three criteria are often deemed to have mild SUD. [8]
Legal cannabis (marijuana) product. Overconsumption and reliance could lead to cannabis-induced amotivational syndrome. The term amotivational syndrome was first devised to understand and explain the diminished drive and desire to work or compete among the population of youth who are frequent consumers of cannabis and has since been researched through various methodological studies with this ...
Developing cannabis use disorder is also a possibility when using marijuana, Kelm says. “Addiction, or cannabis use disorder, develops in about 10% of users,” he says. “Initiating cannabis ...
Marijuana use disorder is common in Washington, where weed is legal, and more severe in people who use both medical and recreational marijuana.
The more recently published DSM-5 combined substance abuse and substance dependence into a single continuum; this is simply known as substance use disorder and requires more presenting symptoms before a diagnosis is made. It also considers each different substance as its own separate disorder, based upon the same basic criteria.
While cannabis is generally considered a calming drug, a recent study found heavy use could have the opposite effect — potentially worsening anxiety and associated disorders.
The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), is the 2013 update to the Diagnostic and Statistical Manual of Mental Disorders, the taxonomic and diagnostic tool published by the American Psychiatric Association (APA). In 2022, a revised version was published. [1]